Kainomyx
Kainomyx is a platform biotechnology company that applies cytoskeletal biology to discover and develop small-molecule therapeutics and diagnostic tests for parasitic diseases with applications in human, veterinary, and agricultural health. The company combines expertise in molecular motor/cytoskeleton biology with biochemical and biophysical screening approaches and operates research sites in the United States and India.
Industries
Nr. of Employees
small (1-50)
Services
In-house discovery and preclinical advancement of small-molecule programs that target parasite cytoskeletal components and molecular motors.
Development of assays intended to detect asymptomatic parasite carriers to support public-health screening and control measures in endemic regions.
In-house discovery and preclinical advancement of small-molecule programs that target parasite cytoskeletal components and molecular motors.
Development of assays intended to detect asymptomatic parasite carriers to support public-health screening and control measures in endemic regions.
Expertise Areas
- Antiparasitic small-molecule drug discovery
- Cytoskeletal and molecular motor biology
- Biochemical and biophysical assay development
- Diagnostic assay development for parasitic diseases
Key Technologies
- Cytoskeletal / molecular motor assays
- Small-molecule screening
- Biochemical assays
- Biophysical measurement techniques
News & Updates
Announcement of a non-binding memorandum of understanding for joint development and commercialization of an antimalarial drug, subject to a definitive agreement.
Establishment of a wholly owned research subsidiary in the C-CAMP incubator on the NCBS campus in Bangalore, India.
Moved into modernized research space at 3160 Porter Drive, Palo Alto (Stanford Research Park) to support early- and growth-stage life science activities.
Profiled as a top startup combining parasite biology with biochemical and biophysical approaches to target parasite cytoskeleton proteins and offering tests to identify asymptomatic carriers.
Company mentioned in a Forbes article about impact investing and companies addressing global health challenges.
Raised $6 million to advance malaria therapeutics and programs in diagnosis and other parasitic diseases.
Announcement of a non-binding memorandum of understanding for joint development and commercialization of an antimalarial drug, subject to a definitive agreement.
Establishment of a wholly owned research subsidiary in the C-CAMP incubator on the NCBS campus in Bangalore, India.
Moved into modernized research space at 3160 Porter Drive, Palo Alto (Stanford Research Park) to support early- and growth-stage life science activities.
Profiled as a top startup combining parasite biology with biochemical and biophysical approaches to target parasite cytoskeleton proteins and offering tests to identify asymptomatic carriers.
Company mentioned in a Forbes article about impact investing and companies addressing global health challenges.
Raised $6 million to advance malaria therapeutics and programs in diagnosis and other parasitic diseases.